Our results showed that FDX1 was dysregulated in 17 types of cancer, and IHC analysis confirmed this tendency at the protein level in thyroid cancer, colorectal cancer, and liver cancer. This evidence concerns the gene FDX1 and thyroid gland carcinoma.